Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem BioNTech […]readmore
Tags : MannKind
Shots: The NDA is based on data from the BREEZE study evaluating Tyvaso DPI in 51 patients with PAH transitioning from Tyvaso inhalation solution which demonstrates the safety & tolerability […]readmore
Shots: MannKind and One Drop collaborate to integrate MannKind’s BluHale, a Bluetooth connected accessory attached to Afrezza inhaler in to the One drop platform. In H1’19, One drop announced clinical […]readmore